Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis

Authors:
  • GBGabriela M Baerlocher
    Gabriela M Baerlocher
  • BBBart Burington
    Bart Burington
  • DSDavid S Snyder
    David S Snyder

Abstract
To the Editor: Baerlocher et al. (Sept. 3 issue)1 report on telomere-targeted treatment with imetelstat in 18 patients with essential thrombocythemia. The drug was effective in controlling platelet levels in all patients, albeit often at the expense of hemoglobin and neutrophil levels. However, the other main treatment goals in essential thrombocythemia2 — controlling symptoms and preventing both disease progression and thromboembolic complications — were definitely not achieved. Fatigue, diarrhea, and nausea were all reported by more than 70% of the patients. A total of 3 patients had progression to myelofibrosis, and 2 patients had a thromboembolic event. Thus, treatment with . . .

This publication has 11 references indexed in Scilit: